Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Galaxy Biotech LLC

http://www.galaxybiotech.com/

Latest From Galaxy Biotech LLC

Deals Shaping The Medical Industry, November 2012

The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, medical devices, pharmaceuticals, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

BioPharmaceutical Medical Device

Deals Of The Week: Roche/Galaxy, Mallinckrodt/CNS Therapies, Valeant/QLT

Cardiome may go it alone with atrial fibrillation drug vernakalant after Merck exited a 2009 partnership around the drug, but another possibility is that Cardiome will seek a buyer.

BioPharmaceutical Deals

Roche adds Galaxy FGF2 MAbs to complement internal project

Roche has licensed exclusive worldwide development and commercialisation rights to Galaxy Biotech's antibodies targeting fibroblast growth factor 2 (FGF2) for the treatment of cancer.

Cancer
See All

Company Information

  • Industry
  • Distributors
  • Pharmaceuticals
  • Services
  • Biotechnology
    • Large Molecule
      • Antibodies
UsernamePublicRestriction

Register